Last reviewed · How we verify

PCA Ketamine — Competitive Intelligence Brief

PCA Ketamine (PCA Ketamine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist. Area: Anesthesia.

marketed NMDA receptor antagonist NMDA receptor Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

PCA Ketamine (PCA Ketamine) — Universidad de Antioquia. PCA Ketamine is a patient-controlled anesthesia formulation of ketamine that acts as an NMDA receptor antagonist to produce dissociative anesthesia and analgesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PCA Ketamine TARGET PCA Ketamine Universidad de Antioquia marketed NMDA receptor antagonist NMDA receptor
Namenda MEMANTINE AbbVie marketed N-methyl-D-aspartate Receptor Antagonist Glutamate NMDA receptor; GRIN1/GRIN2A 2003-01-01
Felbatol FELBAMATE Mylan Speciality Lp marketed Anti-epileptic Agent [EPC] NMDA receptor-ionophore complex 1993-01-01
QUINIDINE QUINIDINE marketed sigma-1 receptor, NMDA receptor, CYP2D6 1950-01-01
Methadone Hydrochloride METHADONE Specgx Llc marketed Opioid Agonist mu-opioid receptors, NMDA receptor 1947-01-01
Dexmedetomidine-esketamine combination Dexmedetomidine-esketamine combination Peking University First Hospital marketed Sedative-analgesic combination Alpha-2 adrenergic receptor; NMDA receptor
dexter ketamine dexter ketamine Federal University of São Paulo marketed NMDA receptor antagonist NMDA receptor (glutamate-gated ion channel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist class)

  1. Turku University Hospital · 3 drugs in this class
  2. H. Lundbeck A/S · 2 drugs in this class
  3. Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
  4. Shalvata Mental Health Center · 2 drugs in this class
  5. New York State Psychiatric Institute · 2 drugs in this class
  6. Auris Medical AG · 1 drug in this class
  7. AstraZeneca · 1 drug in this class
  8. Alameda Health System · 1 drug in this class
  9. Centre Hospitalier Universitaire de Nice · 1 drug in this class
  10. Asker & Baerum Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PCA Ketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/pca-ketamine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: